MENEST Drug Patent Profile

When do Menest patents expire, and what generic alternatives are available?

Menest is a drug marketed by Monarch Pharms and is included in four NDAs.

The generic ingredient in MENEST is estrogens, esterified. There are three drug master file entries for this compound. Additional details are available on the estrogens, esterified profile page.

Summary for MENEST

US Patents:	0
Applicants:	1
NDAs:	4

US Patents and Regulatory Information for MENEST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Monarch Pharms	MENEST	estrogens, esterified	TABLET;ORAL	084951-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	MENEST	estrogens, esterified	TABLET;ORAL	084949-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	MENEST	estrogens, esterified	TABLET;ORAL	084948-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Monarch Pharms	MENEST	estrogens, esterified	TABLET;ORAL	084950-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Menest Investment Scenario and Fundamentals Analysis

Last updated: August 1, 2026

Menest, an oral esterified-estrogen product, is a mature hormone-replacement therapy with limited standalone investment value. Its clinical utility remains established, but the commercial franchise has little exclusivity, faces generic substitution, and lacks the growth profile associated with novel pharmaceuticals. The investment case depends on low-cost generic manufacturing, portfolio ownership, distribution, or a broader women’s-health platform rather than on Menest brand growth.

What is Menest and how does it work?

Menest is the brand name for esterified estrogens, an orally administered estrogen product used for estrogen-deficiency conditions. Historically, indications included treatment of moderate-to-severe vasomotor symptoms associated with menopause, vulvar and vaginal atrophy, hypoestrogenism, and prevention of postmenopausal osteoporosis where appropriate alternatives were unsuitable.

Esterified estrogens are a mixture of estrogenic compounds, principally estrone sulfate and equilin sulfate. After administration, the compounds are hydrolyzed and converted into active estrogens. The product is available in several strengths, including:

Strength	Typical tablet presentation
Esterified estrogens 0.3 mg	Oral tablet
Esterified estrogens 0.625 mg	Oral tablet
Esterified estrogens 1.25 mg	Oral tablet
Esterified estrogens 2.5 mg	Oral tablet

Menest is not a biologic and does not require biosimilar development. Its competitive products include oral conjugated estrogens, estradiol tablets, transdermal estradiol patches, estrogen creams, vaginal tablets, rings, and compounded hormone products.

What is the FDA status of Menest?

Menest was approved under an FDA new drug application for esterified estrogens. The product has been marketed historically under different corporate owners and has also been exposed to generic substitution.

The principal regulatory facts are:

Regulatory item	Assessment
Active ingredient	Esterified estrogens
Dosage form	Oral tablet
FDA pathway	Original NDA followed by generic ANDA competition
Therapeutic class	Estrogen replacement therapy
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Current commercial profile	Mature, low-growth, generic-exposed
Safety framework	Class-wide estrogen labeling, including boxed warnings

FDA estrogen labeling addresses cardiovascular, cerebrovascular, thromboembolic, breast-cancer, endometrial-cancer and dementia-related risks. The risks vary by formulation, dose, duration, route of administration, and whether a progestogen is used in a patient with an intact uterus. The Women’s Health Initiative materially changed the commercial environment for systemic hormone therapy and reduced the attractiveness of older estrogen products as broad preventive therapies. [1]

When does Menest lose exclusivity?

Menest has already lost practical market exclusivity. The product is based on an old small-molecule estrogen mixture, and any original composition or product patents would have expired decades ago. Its commercial position is therefore determined by generic competition, manufacturing economics, supply reliability, brand recognition, and payer substitution.

Menest does not have a meaningful remaining period of regulatory exclusivity comparable to:

• New chemical entity exclusivity;
• Orphan-drug exclusivity;
• Pediatric exclusivity;
• New-product exclusivity;
• Biologic reference-product exclusivity.

The relevant commercial question is no longer the expiration of a blocking patent. It is whether the branded product remains listed and supplied, whether generic esterified estrogens are available, and whether prescribers continue to request the Menest name.

What patents protect Menest?

No current patent moat is apparent for the underlying esterified-estrogen active ingredient. The product is based on a long-established estrogen mixture, and the core composition is in the public domain.

Potential historical intellectual-property categories included:

Patent category	Current investment relevance
Active-ingredient composition	No meaningful remaining exclusivity
Tablet formulation	Likely expired or commercially non-blocking
Manufacturing process	Could affect cost or quality, but not normally prevent generic entry
Method of use	Historical menopause and estrogen-deficiency claims have little remaining blocking value
Packaging or labeling	Limited value and generally avoidable by competitors
Brand trademark	May protect the Menest name, not the active ingredient

A generic applicant can generally compete by relying on an abbreviated new drug application if it demonstrates pharmaceutical equivalence and bioequivalence to the reference product. A generic company does not need to copy the Menest trademark, packaging, or every commercial attribute.

What is the Orange Book status of Menest?

The Orange Book is relevant because it records FDA-approved reference products, therapeutic-equivalence information, and certain patent or exclusivity information. Menest’s historical listing is more important than its prospective patent value.

The commercial implications are:

1. Any active Orange Book patent listing would need to be reviewed against current FDA records.
2. Historical listing does not create ongoing exclusivity after patent expiration.
3. Generic esterified-estrogen products can obtain approval through ANDA procedures if the reference-product requirements are satisfied.
4. A brand product can remain FDA-approved while having little or no commercial share.

The FDA Orange Book distinguishes regulatory approval from market protection. Approval confirms that the product meets applicable safety, efficacy, quality, and manufacturing standards. It does not guarantee brand demand or price protection. [2]

Are there Paragraph IV challenges to Menest?

Paragraph IV litigation is unlikely to be a material current issue for Menest. Paragraph IV certifications are most relevant when a generic applicant challenges an unexpired Orange Book patent. For an old estrogen product with expired core intellectual property, generic companies can generally enter without creating a major patent dispute.

The likely competitive pathway is:

Event	Commercial effect
ANDA filing	Establishes potential generic competition
Paragraph III certification	Delays launch until listed patent expiry
Paragraph IV certification	Can trigger patent litigation and a 30-month stay
Approval after patent expiry	Permits launch, subject to regulatory status
Multiple generic approvals	Accelerates price erosion
Brand withdrawal	Can reduce reference-brand availability but not eliminate generic supply

No prominent recent Paragraph IV campaign involving Menest is central to the investment thesis. The absence of active patent litigation supports the conclusion that Menest is a mature generic-exposed product rather than a litigation-protected asset.

What formulations are protected by Menest?

Menest’s primary formulation is an immediate-release oral tablet. The product does not have a differentiated long-acting injection, transdermal delivery system, vaginal ring, implant, or proprietary controlled-release platform.

This limits formulation-based pricing power. Competing estrogen delivery systems include:

Product type	Competitive advantage
Oral esterified estrogens	Familiar administration and broad historical use
Oral estradiol	Widely available and often lower cost
Transdermal estradiol	Avoids first-pass hepatic exposure and offers patch or gel delivery
Vaginal estrogen	Local treatment with lower systemic exposure than systemic therapy
Estrogen-progestogen combinations	May simplify therapy for patients requiring endometrial protection
Compounded hormones	Custom dosing, but with different regulatory and quality considerations

The absence of a proprietary delivery system is a major weakness in the Menest asset profile.

How strong is the Menest patent estate?

The patent estate is weak from an investment perspective.

Patent-strength assessment

Factor	Rating	Reason
Composition-of-matter protection	Very weak	Legacy estrogen mixture
Remaining patent term	Very weak	Core rights are long expired
Formulation differentiation	Weak	Conventional oral tablet
Regulatory exclusivity	None of practical importance	Mature approved product
Generic substitution resistance	Weak	Multiple alternative estrogen products
Manufacturing barrier	Moderate at most	Quality and supply controls matter, but entry is feasible
Trademark value	Low to moderate	Brand recognition may persist in limited segments
Litigation leverage	Very weak	No apparent blocking patent platform

The most defensible asset would be a reliable, approved, low-cost supply position rather than a patent estate.

What generic entry risks exist for Menest?

Generic substitution is the primary commercial risk. Generic entry affects both volume and price:

• Pharmacy benefit managers can substitute lower-priced esterified estrogens.
• Physicians can prescribe estradiol instead of esterified estrogens.
• Patients may switch to transdermal or vaginal products.
• Payers can favor products with lower net cost or a more favorable safety profile.
• Retail pharmacies may not maintain inventory of a low-volume branded product.

Menest also faces therapeutic substitution, not only direct generic substitution. Oral estradiol and transdermal estradiol are clinically familiar alternatives. A product can lose share even if no direct esterified-estrogen generic is available.

What is the competitive landscape for Menest?

Menest competes in a fragmented menopausal hormone-therapy market.

Direct competitors

Direct competitors include generic esterified estrogens and other oral estrogen products. Their competitive advantages are usually lower price, established pharmacy access, and broad payer coverage.

Indirect competitors

Indirect competitors include:

• Generic estradiol tablets;
• Estradiol patches and gels;
• Conjugated estrogens;
• Vaginal estrogen creams, tablets, and rings;
• Selective estrogen receptor modulators;
• Nonhormonal therapies for vasomotor symptoms;
• Compounded hormone preparations.

The market has shifted toward route-specific prescribing. Patients seeking systemic symptom control may receive oral or transdermal estrogen, while those with primarily genitourinary symptoms may receive local vaginal therapy. Menest therefore competes against products with different pharmacokinetic and safety profiles, not only against chemically similar tablets.

What are the revenue fundamentals for Menest?

Menest has limited public-company revenue visibility. A branded product of this age is unlikely to disclose material standalone revenue unless it is part of a larger women’s-health portfolio. Generic esterified-estrogen sales are also generally reported within broader product categories rather than as separately disclosed assets.

Fundamental investment indicators

Indicator	Assessment
Market growth	Low to modest
Volume outlook	Flat to declining for legacy oral brands
Pricing power	Low
Gross-margin potential	Dependent on manufacturing scale
Regulatory cost	Manageable but ongoing
Patent-driven value	Minimal
Working-capital risk	Inventory and supply-chain dependent
Brand value	Niche rather than franchise-scale
M&A value	Portfolio add-on only
Near-term catalyst	Supply, licensing, or portfolio transaction rather than patent expiry

The economic value of Menest is more likely to come from stable cash generation in a small established market than from rapid revenue growth. A buyer would need to assess net sales, gross margin, customer concentration, product liability exposure, manufacturing cost, and generic price competition.

What licensing deals affect Menest?

Menest has historically changed hands through broader corporate transactions and women’s-health portfolio transfers rather than through a major technology license. The product’s value in a transaction would normally be assessed as part of a portfolio containing other hormone-therapy products.

Potential transaction structures include:

• Brand acquisition with regulatory rights;
• In-licensing of U.S. commercial rights;
• Contract manufacturing and supply agreements;
• Acquisition of an approved NDA and associated trademarks;
• Portfolio divestiture by a larger pharmaceutical company;
• Generic rights acquisition through an ANDA owner.

A licensee should focus on the right to manufacture, distribute, relabel, and maintain the FDA application. Since patent protection is limited, contractual supply rights and regulatory ownership are more important than patent exclusivity.

What patent litigation affects Menest?

Menest does not appear to have a current litigation profile that changes its fundamental valuation. The main legal exposures are more likely to involve:

• Product liability claims associated with estrogen-class risks;
• Labeling and pharmacovigilance obligations;
• Manufacturing and quality-system compliance;
• Distribution contracts;
• Trademark ownership;
• Generic approval disputes, if a future applicant challenges a listed patent.

The absence of meaningful patent litigation reduces legal execution risk but also removes a potential catalyst for delayed generic entry.

What generic launch scenarios exist for Menest?

Base case

Menest remains a niche or discontinued branded product while generic esterified estrogens and alternative estrogen therapies supply the market. Prices remain competitive, and revenue is stable only where prescribers or patients retain brand preference.

Downside case

The branded product loses distribution, a generic supply interruption is resolved, or payers increase substitution. Menest sales decline rapidly, with little ability to recover pricing.

Upside case

A specialty-pharma owner acquires the product at a low valuation, restores reliable supply, targets a defined menopause or women’s-health channel, and combines Menest with other products. The upside would come from portfolio synergies and improved commercialization, not from patent protection.

How does Menest compare with estradiol and Premarin?

Attribute	Menest	Generic estradiol	Premarin
Active ingredient	Esterified estrogens	Estradiol	Conjugated estrogens
Dosage forms	Primarily oral tablets	Oral, transdermal, vaginal and other forms	Oral and vaginal products
Patent strength	Weak or expired	Generally mature and genericized	Brand and product-specific rights vary
Delivery differentiation	Limited	Stronger route diversity	Broader branded franchise
Generic pressure	High	High	Varies by product
Pricing power	Low	Low	Higher in selected branded segments
Investment profile	Niche mature product	Commodity-to-specialty generic market	Larger branded women’s-health platform

Menest has less commercial differentiation than products with transdermal delivery, vaginal administration, or combination therapy. Its principal advantage is historical familiarity, not technology.

Is Menest a viable investment?

Menest is not an attractive standalone growth investment. It can be viable as a low-cost portfolio asset if the acquisition price reflects:

• Minimal patent value;
• High generic substitution;
• Limited standalone revenue disclosure;
• Low expected market growth;
• Regulatory maintenance obligations;
• Potential product-liability exposure;
• Dependence on reliable manufacturing and distribution.

A buyer should value Menest using a conservative mature-product framework. The appropriate drivers are cash flow retention, supply cost, inventory turnover, payer mix, channel access, and regulatory compliance. Patent-expiry models and blockbuster peak-sales assumptions are inappropriate.

Key Takeaways

• Menest is an old oral esterified-estrogen product with limited differentiation.
• Practical market exclusivity has already ended.
• The core active ingredient and conventional tablet formulation do not provide a meaningful current patent moat.
• Biosimilar risk is irrelevant because Menest is a small molecule, not a biologic.
• Generic and therapeutic substitution are the main commercial risks.
• FDA approval does not imply current commercial strength or brand-level pricing power.
• The product has limited standalone revenue visibility.
• The most credible upside comes from portfolio ownership, supply reliability, or women’s-health distribution synergies.
• Menest is better viewed as a mature specialty or generic asset than as an innovation-driven pharmaceutical investment.

FAQs

Is Menest still available in the United States?

Availability depends on the current marketing status, manufacturer, wholesaler inventory, and pharmacy sourcing. Esterified-estrogen tablets may remain available through generic or successor products even when the Menest brand has limited distribution.

Is Menest the same as Premarin?

No. Menest contains esterified estrogens, while Premarin contains conjugated estrogens. Both are estrogen products, but their active-ingredient composition, regulatory history, labeling, and commercial positioning differ.

Can a generic company launch esterified estrogens without a Menest patent settlement?

Yes, if the generic applicant has an approved ANDA and no unexpired enforceable patent or regulatory exclusivity blocks launch. A settlement is not inherently required for an old product with no effective blocking patent.

Does Menest have biosimilar competition?

No. Biosimilars apply to biological products. Menest is a chemically manufactured small-molecule estrogen product and competes with generic drugs and therapeutic alternatives.

What would make Menest attractive in an acquisition?

The strongest acquisition case would involve a low purchase price, verified regulatory rights, dependable manufacturing, favorable supply economics, existing specialty-pharmacy access, and cross-selling opportunities with other women’s-health products.

References

1. U.S. Food and Drug Administration. (2003). Estrogen and estrogen with progestin therapies: FDA announces findings from the Women’s Health Initiative.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Menest and esterified estrogens prescribing information.
4. U.S. National Library of Medicine. (2024). DailyMed: Esterified estrogens tablets labeling.
5. U.S. Food and Drug Administration. (2024). Approved drug products and abbreviated new drug application guidance.